scholarly journals TGF-Beta Responsive Gene Signature

2020 ◽  
Author(s):  
Keyword(s):  
Gene Signature ◽  
Tgf Beta ◽  
Responsive Gene

scholarly journals A TGFβ-Responsive Gene Signature Is Associated with a Subset of Diffuse Scleroderma with Increased Disease Severity

2010 ◽  
Vol 130 (3) ◽  
pp. 694-705 ◽  
Author(s):  
Jennifer L. Sargent ◽  
Ausra Milano ◽  
Swati Bhattacharyya ◽  
John Varga ◽  
M. Kari Connolly ◽  
...  
Keyword(s):  
Disease Severity ◽  
Gene Signature ◽  
Diffuse Scleroderma ◽  
Responsive Gene

scholarly journals Molecular Cloning of cDNA for Caprine βig-h3, a TGF-β Responsive Gene, and its Expression in the Uterus of Shiba Goats (Capra hircus var Shiba)

1999 ◽  
Vol 45 (2) ◽  
pp. 135-141 ◽  
Author(s):  
Yong-Jin Kim ◽  
Keitaro Yamanouchi ◽  
Takamasa Uekita ◽  
Toru Sawasaki ◽  
Hideaki Tojo ◽  
...  
Keyword(s):  
Molecular Cloning ◽  
Capra Hircus ◽  
Tgf Beta ◽  
Responsive Gene

scholarly journals Mitochondrial defect-responsive gene signature in liver-cancer progression

BMB Reports ◽  
2015 ◽  
Vol 48 (11) ◽  
pp. 597-598 ◽  
Author(s):  
Young-Kyoung Lee ◽  
Hyun Goo Woo ◽  
Gyesoon Yoon
Keyword(s):  
Liver Cancer ◽  
Cancer Progression ◽  
Gene Signature ◽  
Responsive Gene ◽  
Mitochondrial Defect

scholarly journals 332 Novel TGF-β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A358-A358
Author(s):  
Keun-Wook Lee ◽  
Young Suk Park ◽  
Joong Bae Ahn ◽  
Jin Kyung Lee ◽  
Jiyeon Ryu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Transforming Growth Factor ◽  
Molecular Subtype ◽  
Medical Center ◽  
Objective Response ◽  
Gene Signature ◽  
P Value ◽  
Gene Expressions ◽  
Ifn Γ ◽  
Responsive Gene

BackgroundDual inhibition of transforming growth factor beta (TGF-β) signaling and PD-1 is a promising strategy to reverse immunosuppressive tumor microenvironment and poor responses to immunotherapy. Based on preliminary clinical data with vactosertib, a highly selective and potent inhibitor of TGF-β receptor type 1, in combination with pembrolizumab, this study aimed to explore a biomarker with predictive value for this regimen in metastatic microsatellite stable (MSS) colorectal cancer (CRC).MethodsTumor biopsy samples were obtained from 24 CRC patients at baseline and cycle 2 in the ongoing MP-VAC-204 study and analyzed by RNAseq and DNAseq. Consensus molecular subtype (CMS), TGF-β responsive gene signatures, IFN-γ signatures, and tumor mutation burden (TMB) were analyzed. Clinically benefited patients were defined by those who achieved objective response assessed by RECIST v1.1/iRECIST or progression free survival more than 24 weeks. Vactosertib responsive gene signature (VRGS) that showed significantly different expression among previously identified TGF-β responsive gene signature and IFN-γ signature in responders than in non-responders was identified and VRGS score was calculated by a mean value of VRGS filtered-in gene expressions divided by 6 house-keeping gene expressions.ResultsAs of July 1, 2020, of the total evaluable 24 patients, 71% were CMS4 subtype and 33% were with high TMB (≥10 mut/Mb). Clinical benefit rate was 33.3% including 3 PR and 1 iPR patients. No significant associations in response rate were observed with CMS subtypes or TMB status. VRGS score was significantly enriched in responders than in non-responders (P value = 0.006; AUC = 0.836). A preliminary cut-off value of 2.179 resulted in 94% specificity and 75% sensitivity with 85.7% patients correctly classifying as a responder. After treatment of vactosertib plus pembrolizumab, TGF-β-related VRGS was significantly decreased and the extent of decrease was greater in responders, compared to non-responders.Ethics ApprovalThe study was approved by Ethics Board of Asan Medical Center, Yonsei University College of Medicine, Samsung Medical Center, and Seoul National University Bundang Hospital with approval number 2018-1215, 4-2018-0728, SMC 2018-07-146-006, and B-1808/487-003, respectively.ConclusionsDevelopment of VRGS as a predictive biomarker for this combination treatment with vactosertib and pembrolizumab is ongoing and its potential clinical utility for patient selection will be explored.Trial RegistrationNCT03724851

scholarly journals Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes

Oncotarget ◽  
2015 ◽  
Vol 7 (1) ◽  
pp. 323-341 ◽  
Author(s):  
Kelly E. Craven ◽  
Jesse Gore ◽  
Julie L. Wilson ◽  
Murray Korc
Keyword(s):  
Pancreatic Cancer ◽  
Gene Signature ◽  
Human Pancreatic Cancer ◽  
Tgf Beta ◽  
Angiogenic Gene

Defects in TGF beta signaling by smad 4 and ELF spectrins are associated with gastric carcinogenesis

2001 ◽  
Vol 120 (5) ◽  
pp. A495-A495
Author(s):  
Y GANG ◽  
S DANOVITCH ◽  
T FLEURY ◽  
B MISHRA ◽  
C DENG ◽  
...  
Keyword(s):  
Gastric Carcinogenesis ◽  
Tgf Beta
Sign in / Sign up

Export Citation Format

Share Document